82821-47-4 Usage
Description
(±)-N-(2-hydroxyethyl)-2-[4-(2-methylpropyl)phenyl]propionamide, also known as Aminoprofen, is an amide of ibuprofen with both anti-arthritic and analgesic properties. It is a chiral compound with two enantiomers, which have the same molecular formula but different spatial arrangements of atoms. This makes it a versatile and effective compound for various applications.
Uses
Used in Pharmaceutical Industry:
(±)-N-(2-hydroxyethyl)-2-[4-(2-methylpropyl)phenyl]propionamide is used as a topical anti-arthritic agent for the treatment of arthritis and related conditions. It helps alleviate pain and inflammation associated with arthritis, providing relief to patients suffering from joint pain and stiffness.
Used in Pain Management:
(±)-N-(2-hydroxyethyl)-2-[4-(2-methylpropyl)phenyl]propionamide is used as an analgesic for the management of mild to moderate pain. It is comparable to other pain-relieving agents such as methyl salicylate in various pain models, making it a promising candidate for pain management applications.
Used in Research and Development:
(±)-N-(2-hydroxyethyl)-2-[4-(2-methylpropyl)phenyl]propionamide is used in research and development for the study of its chiral properties and potential applications in various fields. Its unique structure and properties make it an interesting subject for scientific investigation and potential development of new drugs and therapies.
Originator
Aldo-Union (Spain)
Check Digit Verification of cas no
The CAS Registry Mumber 82821-47-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,8,2 and 1 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 82821-47:
(7*8)+(6*2)+(5*8)+(4*2)+(3*1)+(2*4)+(1*7)=134
134 % 10 = 4
So 82821-47-4 is a valid CAS Registry Number.
InChI:InChI=1/C15H23NO2/c1-11(2)10-13-4-6-14(7-5-13)12(3)15(18)16-8-9-17/h4-7,11-12,17H,8-10H2,1-3H3,(H,16,18)
82821-47-4Relevant articles and documents
NSAIDs do not require the presence of a carboxylic acid to exert their anti-inflammatory effect – why do we keep using it?
Ullah, Nasir,Huang, Zhangjian,Sanaee, Forough,Rodriguez-Dimitrescu, Alexandra,Aldawsari, Fahad,Jamali, Fakhreddin,Bhardwaj, Atul,Islam, Nazar Ul,Velázquez-Martínez, Carlos A.
, p. 1018 - 1028 (2016/10/09)
The carboxylic acid group (–COOH) present in classical NSAIDs is partly responsible for the gastric toxicity associated with the administration of these drugs. This concept has been extensively proven using NSAID prodrugs. However, the screening of NSAIDs
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors
Allegretti, Marcello,Bertini, Riccardo,Cesta, Maria Candida,Bizzarri, Cinzia,Di Bitondo, Rosa,Di Cioccio, Vito,Galliera, Emanuela,Berdini, Valerio,Topai, Alessandra,Zampella, Giuseppe,Russo, Vincenzo,Di Bello, Nicoletta,Nano, Giuseppe,Nicolini, Luca,Locati, Massimo,Fantucci, Piercarlo,Florio, Saverio,Colotta, Francesco
, p. 4312 - 4331 (2007/10/03)
The CXC chemokine CXCL8/IL-8 plays a major role in the activation and recruitment of polymorphonuclear (PMN) cells at inflammatory sites. CXCL8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2). (R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCLS-induced human PMNs chemotaxis. We report here molecular modeling studies showing a putative interaction site of 1 in the TM region of CXCR1. The binding model was confirmed by alanine scanning mutagenesis and photoaffinity labeling experiments. The molecular model driven medicinal chemistry optimization of 1 led to a new class of potent and specific inhibitors of CXCL8 biological activity. Among these, repertaxin (13) was selected as a clinical candidate drug for prevention of post-ischemia reperfusion injury.
